FDA Dumps 'Animal Testing' Term for Woke 'Nonclinical' Lingo
Published Date: 9/22/2026
Rule
Summary
The FDA is updating its rules to replace the words “animal” tests with “nonclinical” tests, making room for new, smarter ways to check drug safety without relying only on animal testing. This change affects drug makers and researchers but won’t add new costs or requirements. The rule kicks in on February 4, 2027, and comments are open until December 7, 2026.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Terminology Update Lets More Test Types
FDA is replacing references to “animal” and some uses of “preclinical” with the term “nonclinical” and is adding definitions for “nonclinical test” and “nonclinical study.” The change explicitly includes tests done in vitro, in silico, in chemico, organ chips, computer modeling, and animal tests, and may foster use of new approach methodologies (NAMs). The rule is effective February 4, 2027 and the comment period ends December 7, 2026.
No New Testing Costs or Requirements
FDA states this direct final rule adds no new regulatory requirements and is expected to generate no costs for industry. The Agency describes the change as noncontroversial and effective February 4, 2027, with comments accepted through December 7, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-19329, Radio Broadcasting Services; Various Locations
The FCC is bringing back some empty FM radio channels in different towns because previous licenses were canceled. These channels meet all the rules and are ready for new applications, but the FCC isn’t accepting applications just yet. This change starts on September 22, 2026, and could open new chances for radio stations soon.
Next: 2026-19389, Softwood Lumber Board Assessment Rate Clarification and Changes to Membership
Starting October 22, 2026, the Softwood Lumber Board is updating how it charges fees on imported softwood lumber and changing who gets to be on the Board. If you import softwood lumber or are involved with the Board, these changes could affect your costs and membership rules. This update keeps the lumber industry running smoothly and fairly.